antibody against osteocalcin (TaKaRa)


Structured Review

Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Dexamethasone Enhances Osteogenic Differentiation of Bone Marrow- and Muscle-Derived Stromal Cells and Augments Ectopic Bone Formation Induced by Bone Morphogenetic Protein-2"
Article Title: Dexamethasone Enhances Osteogenic Differentiation of Bone Marrow- and Muscle-Derived Stromal Cells and Augments Ectopic Bone Formation Induced by Bone Morphogenetic Protein-2
Journal: PLoS ONE
doi: 10.1371/journal.pone.0116462

Figure Legend Snippet: RT-PCR primers used in this study.
Techniques Used:

Figure Legend Snippet: A: Schematic representation of the cell culture protocol. Gross images of ALP staining (ALP) and Von Kossa staining (VK) of BMSCs (B) and MuSCs (D). Quantitative analysis of the mRNA expression of ALP and osteocalcin in BMSCs (C) and MuSCs (E). The fold change in gene expression was normalized to that of BM-Dex-AG or Mu-Dex-AG. Bars show the mean and SEM. Statistical significance was confirmed between the BM and BM-Dex groups (ALP: p = 0.015, OCN: p = 0.023) and between the Mu and Mu-DEX groups (ALP: p = 0.019, OCN: p = 0.015). Effects of combinations of differentiation reagents were significant for ALP in BM-Dex (p = 0.032) and Mu-DEX (p = 0.019) and for OCN in Mu-DEX (p = 0.024).
Techniques Used: Cell Culture, Staining, Expressing

Figure Legend Snippet: A: Bone formation capability of muscle-derived cells. Representative histological sections of a scaffold loaded with BMSCs or MuSCs cultured with both dexamethasone and BMP-2. Scale bar: 1 mm (left panels), 200 μm (middle panels) and 50 μm (right panels). Black arrows indicate new bone formation in the scaffold. Black arrow heads indicate osteocytes and green arrow heads indicate bone lining cells. B: Newly formed bone, T: β-TCP, P: Porous area. B: Recruitment of cells residing in muscle tissue to participate in BMP-2-induced ectopic bone formation. Cells labeled prior to local BMP-2 administration were detected in the newly formed woven bone area. Representative histological sections were stained with H&E and evaluated for i-QD fluorescence. The black arrows in the H&E image show the locations of fluorescently labeled cells indicated with white arrows in the fluorescent image. Scale bar: 200 μm. B: Newly formed bone, T: β-TCP, P: Porous area. C: Augmentation of ectopic bone formation by dexamethasone. C-1, 2: Representative histological sections of an excised scaffold that had been loaded with BMP-2 alone and a scaffold that had been loaded with dexamethasone and BMP-2. The sections were stained with H&E and immunostained for osteocalcin. Black arrows indicate new bone formation in the scaffold. Red arrows indicate osteocalcin positive staining area. Scale bar: 1 mm (top panels of C-1), 200 μm (bottom panels of C-1) and 50 μm (C-2). B: Newly formed bone, T: β-TCP, P: Porous area. C-3: Quantification of bone formation at 3 weeks after transplantation. The Y axis indicates the bone formation ratio calculated as total bone area/total scaffold area. Each bar represents the mean with the standard deviation (SD). *denotes P < 0.05.
Techniques Used: Derivative Assay, Cell Culture, Labeling, Staining, Fluorescence, Transplantation Assay, Standard Deviation
antibody against osteocalcin (TaKaRa)


Structured Review

Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Bone marrow mesenchymal stem cells derived exosomal miRNAs can modulate diabetic bone-fat imbalance"
Article Title: Bone marrow mesenchymal stem cells derived exosomal miRNAs can modulate diabetic bone-fat imbalance
Journal: Frontiers in Endocrinology
doi: 10.3389/fendo.2023.1149168

Figure Legend Snippet: Diabetic mice show imbalanced bone formation and marrow fat accumulation. (A) Representative micro-computed tomography (μCT) image of femurs from 3-month male diabetic (db/db) and normal (db/m) mice. (B-E) Quantitative μCT analysis of trabecular bone volume (B) , Trabecular bone number (C) , Trabecular thickness (D) and Trabecular separation (E) . Scale bar: 1 mm (F, G) Representative images of osteocalcin immunohistochemical staining (F) and number of osteoblasts in the distal femur (G) , red arrows represent osteocalcin-positive–staining cells. Scale bar: 100 μm. (H, I) Representative images of H&E staining (H) and area of adipose cells in the distal femur (I) . Scale bar: 100 μm. The data is shown as the mean ± SD. * P <0.05, ** P <0.01, Welch’s t test is used in (B) and (I) , Student’s t-test used for other figures, n=6 per group.
Techniques Used: Micro-CT, Immunohistochemical staining, Staining

Figure Legend Snippet: Overexpression of miR-221 in normal mice showed bone loss and marrow fat accumulation. (A-F) Intramedullary injection of 30ul 1.0E+12 vg/ml AAV-microRNA-NC-EGFP and AAV-microRNA-221-EGFP in normal mice, six weeks after AAV injection, the femur were collected for further analysis. Representative fluorescent images of GFP expression, blue fluorescence marks the DAPI-labeled nucleus and green fluorescence indicates successful virus injection (A) . Scale bar: 5mm; Representative micro-computed tomography (μCT) image (B) ; Quantitative μCT analysis of trabecular bone volume (C) , Trabecular bone number (D) , Trabecular thickness (E) and Trabecular separation (F) , NC, normal control, n=6 per group. Scale bar: 1mm. (G, H) Representative images of osteocalcin immunohistochemical staining (G) and number of osteoblasts in the distal femur (H) , red arrows represent osteocalcin-positive–staining cells. Scale bar: 100 μm. (I, J) Representative images of H&E staining and area of adipose cells in the distal femur, respectively. Scale bar: 100 μm. The data is shown as the mean ± SD. * P <0.05, ** P <0.01 (ANOVA).
Techniques Used: Over Expression, Injection, Expressing, Fluorescence, Labeling, Micro-CT, Immunohistochemical staining, Staining

Figure Legend Snippet: Aptamer-BMSCs-Exos alleviated bone-fat imbalance in diabetic mice. (A, B) Conjugate normal BMSCs-Exos with BMSCs-specific aptamer and use near-infrared fluorescent dye DIR to label BMSCs-Exos, then inject 100ug modified exosomes to diabetic mice via tail vein. (A) Representative FMT images of the near-infrared fluorescence signals in organs isolated from mice administered with DIR dye alone, DIR-labeled BMSCs-Exos (DIR-BMSCs-Exos) or aptamer conjugated DIR-labeled BMSCs-Exos (DIR-BMSCs-Exos-Apt) for 4h (up panel) and 12h (bottom panel). (B) Inject 100ug modified exosomes to diabetic mice via tail vein twice a week, representative μCT images of diabetic mouse femora. Scale bar: 1mm. (C-F) Quantitative μCT analysis of trabecular bone volume (C) , Trabecular bone number (D) , Trabecular thickness (E) and Trabecular separation (F) . (G, H) Representative images of osteocalcin immunohistochemical staining (G) and number of osteoblasts in the distal femur (H) , red arrows represent osteocalcin-positive–staining cells. Scale bar: 100 μM. (I, J) Representative images of H&E staining (I) and area of adipose cells in the distal femur (J) . Scale bar: 100 μM. The data is shown as the mean ± SD, n = 6 per group, * P < 0.05 ** P < 0.01 (ANOVA), n=6 per group. NS, not significant.
Techniques Used: Modification, Fluorescence, Isolation, Labeling, Immunohistochemical staining, Staining
antibody against osteocalcin (TaKaRa)


Structured Review

Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Dexamethasone Enhances Osteogenic Differentiation of Bone Marrow- and Muscle-Derived Stromal Cells and Augments Ectopic Bone Formation Induced by Bone Morphogenetic Protein-2"
Article Title: Dexamethasone Enhances Osteogenic Differentiation of Bone Marrow- and Muscle-Derived Stromal Cells and Augments Ectopic Bone Formation Induced by Bone Morphogenetic Protein-2
Journal: PLoS ONE
doi: 10.1371/journal.pone.0116462

Figure Legend Snippet: RT-PCR primers used in this study.
Techniques Used:

Figure Legend Snippet: A: Schematic representation of the cell culture protocol. Gross images of ALP staining (ALP) and Von Kossa staining (VK) of BMSCs (B) and MuSCs (D). Quantitative analysis of the mRNA expression of ALP and osteocalcin in BMSCs (C) and MuSCs (E). The fold change in gene expression was normalized to that of BM-Dex-AG or Mu-Dex-AG. Bars show the mean and SEM. Statistical significance was confirmed between the BM and BM-Dex groups (ALP: p = 0.015, OCN: p = 0.023) and between the Mu and Mu-DEX groups (ALP: p = 0.019, OCN: p = 0.015). Effects of combinations of differentiation reagents were significant for ALP in BM-Dex (p = 0.032) and Mu-DEX (p = 0.019) and for OCN in Mu-DEX (p = 0.024).
Techniques Used: Cell Culture, Staining, Expressing

Figure Legend Snippet: A: Bone formation capability of muscle-derived cells. Representative histological sections of a scaffold loaded with BMSCs or MuSCs cultured with both dexamethasone and BMP-2. Scale bar: 1 mm (left panels), 200 μm (middle panels) and 50 μm (right panels). Black arrows indicate new bone formation in the scaffold. Black arrow heads indicate osteocytes and green arrow heads indicate bone lining cells. B: Newly formed bone, T: β-TCP, P: Porous area. B: Recruitment of cells residing in muscle tissue to participate in BMP-2-induced ectopic bone formation. Cells labeled prior to local BMP-2 administration were detected in the newly formed woven bone area. Representative histological sections were stained with H&E and evaluated for i-QD fluorescence. The black arrows in the H&E image show the locations of fluorescently labeled cells indicated with white arrows in the fluorescent image. Scale bar: 200 μm. B: Newly formed bone, T: β-TCP, P: Porous area. C: Augmentation of ectopic bone formation by dexamethasone. C-1, 2: Representative histological sections of an excised scaffold that had been loaded with BMP-2 alone and a scaffold that had been loaded with dexamethasone and BMP-2. The sections were stained with H&E and immunostained for osteocalcin. Black arrows indicate new bone formation in the scaffold. Red arrows indicate osteocalcin positive staining area. Scale bar: 1 mm (top panels of C-1), 200 μm (bottom panels of C-1) and 50 μm (C-2). B: Newly formed bone, T: β-TCP, P: Porous area. C-3: Quantification of bone formation at 3 weeks after transplantation. The Y axis indicates the bone formation ratio calculated as total bone area/total scaffold area. Each bar represents the mean with the standard deviation (SD). *denotes P < 0.05.
Techniques Used: Derivative Assay, Cell Culture, Labeling, Staining, Fluorescence, Transplantation Assay, Standard Deviation
antibody against osteocalcin (TaKaRa)


Structured Review
Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
antibodies against osteocalcin (TaKaRa)


Structured Review

Antibodies Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against osteocalcin/product/TaKaRa
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Long noncoding RNA Gm31629 promotes bone regeneration by maintaining bone marrow mesenchymal stem cells activity"
Article Title: Long noncoding RNA Gm31629 promotes bone regeneration by maintaining bone marrow mesenchymal stem cells activity
Journal: PeerJ
doi: 10.7717/peerj.13475

Figure Legend Snippet: (A) Time plan for surgical ablation of trabecular bone in distal femoral of mice. (B) Representative micro-CT images. The white square was selected to measure trabecular bone volume in bone regeneration region. (C) Quantification of trabecular bone volume in bone regeneration region. ( n = 6). (D) HE staining of distal femora. Scale bar: 200 µm. (E) Immunohistochemical staining of osteocalcin positive cells. Black arrows represent osteocalcin positive cells. Scale bar: 50 µm. (F) Quantitative analysis of osteocalcin positive cells. ( n = 6). (G) TRAP staining images. Scale bar: 50 µm. (H) Quantitative analysis of TRAP positive cells. ( n = 6). Data are expressed as mean ± sd and statistical differences were analyzed by Student’s t test. ∗∗ p < 0.01; ∗∗∗ p < 0.001.
Techniques Used: Micro-CT, Staining, Immunohistochemical staining

Figure Legend Snippet: (A) Time plan for surgical ablation of trabecular bone in distal femoral of mice. (B) Representative micro-CT images. The white square was selected to measure trabecular bone volume in bone regeneration region. (C) Quantification of trabecular bone volume in bone regeneration region. ( n = 6). (D) HE staining of distal femora. Scale bar: 200 µm. (E) Immunohistochemical staining of osteocalcin positive cells. Black arrows represent osteocalcin positive cells. Scale bar: 50 µm. (F) Quantitative analysis of osteocalcin positive cells. ( n = 6). (G) TRAP staining images. Scale bar: 50 µm. (H) Quantitative analysis of TRAP positive cells. ( n = 6). Data are expressed as mean ± sd and statistical differences were analyzed by Student’s t test. ∗ P < 0.05; ∗∗ P < 0.01; N.S, no significance.
Techniques Used: Micro-CT, Staining, Immunohistochemical staining

Figure Legend Snippet: (A) Time point at which mice were treated with TF2A or vehicle, and performed with surgical ablation of trabecular bone in distal femoral . (B) The body weight of 12-month-old mice before and after treated with TF2A or vehicle. ( n = 6). (C) Representative micro-CT images. The white square was selected to measure trabecular bone volume in bone regeneration region. (D) Quantification of trabecular bone volume in bone regeneration region. ( n = 6). (E) HE staining of distal femora of middle-aged mice. Scale bar: 200 µm. (F) Immunohistochemical staining of osteocalcin positive cells. Black arrows represent osteocalcin positive cells. Scale bar: 50 µm. (G) Quantitative analysis of osteocalcin positive cells. ( n = 6). (H) TRAP staining images. Scale bar: 50 µm. (I) Quantitative analysis of TRAP positive cells. ( n = 6). Data are expressed as mean ± sd and statistical differences were analyzed by Student’s t test. ∗ P < 0.05; N.S, no significance.
Techniques Used: Micro-CT, Staining, Immunohistochemical staining
antibody against osteocalcin (TaKaRa)


Structured Review

Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Octacalcium Phosphate/Gelatin Composite (OCP/Gel) Enhances Bone Repair in a Critical-sized Transcortical Femoral Defect Rat Model"
Article Title: Octacalcium Phosphate/Gelatin Composite (OCP/Gel) Enhances Bone Repair in a Critical-sized Transcortical Femoral Defect Rat Model
Journal: Clinical Orthopaedics and Related Research
doi: 10.1097/CORR.0000000000002257

Figure Legend Snippet: This flow diagram shows the experimental design. OCP/Gel composites and Gel (control) were implanted into rat transcortical femoral defects. Rats were euthanized at 3, 4, and 8 weeks postimplantation. At 3 weeks, histological analysis of undecalcified specimens was performed to observe calcified bone tissues and remaining implants in the defect regions. At 4 and 8 weeks, we measured newly formed bone volumes by micro-CT and histomorphometric analysis of decalcified specimens. At 4 and 8 weeks, the expression of osteoblasts and osteoclast-like cells were quantified by osteocalcin immunostaining and TRAP staining of decalcified specimens, respectively. A color image accompanies the online version of this article.
Techniques Used: Micro-CT, Expressing, Immunostaining, Staining

Figure Legend Snippet: A-H These (A-D) lower-magnification and (E-H) higher-magnification images of bone defect regions were taken of sections with osteocalcin immunostaining (A, B, E, F) at 4 weeks and (C, D, G, H) at 8 weeks after implantation of (A, C, E, G) OCP/Gel composites and (B, D, F, H) Gel. Osteocalcin-positive cells were observed more in the OCP/Gel group than in the Gel group at both 4 and 8 weeks. The open squares indicate the areas shown as magnified images in figures A-D. The black arrows indicate osteocalcin-positive cells. The arrowheads indicate the edge of the defects. (A-D) ×2 magnification, (E-H) ×10 magnification. Scale bars = (A-D) 1 mm and (E-H) 100 µm. A color image accompanies the online version of this article.
Techniques Used: Immunostaining

Figure Legend Snippet: This graph shows quantitative analysis of the number of osteocalcin-positive cells in the defect region after implantation of OCP/Gel composites and Gel at 4 and 8 weeks.
Techniques Used:
antibody against osteocalcin (TaKaRa)


Structured Review

Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Octacalcium Phosphate/Gelatin Composite (OCP/Gel) Enhances Bone Repair in a Critical-sized Transcortical Femoral Defect Rat Model"
Article Title: Octacalcium Phosphate/Gelatin Composite (OCP/Gel) Enhances Bone Repair in a Critical-sized Transcortical Femoral Defect Rat Model
Journal: Clinical Orthopaedics and Related Research
doi: 10.1097/CORR.0000000000002257

Figure Legend Snippet: This flow diagram shows the experimental design. OCP/Gel composites and Gel (control) were implanted into rat transcortical femoral defects. Rats were euthanized at 3, 4, and 8 weeks postimplantation. At 3 weeks, histological analysis of undecalcified specimens was performed to observe calcified bone tissues and remaining implants in the defect regions. At 4 and 8 weeks, we measured newly formed bone volumes by micro-CT and histomorphometric analysis of decalcified specimens. At 4 and 8 weeks, the expression of osteoblasts and osteoclast-like cells were quantified by osteocalcin immunostaining and TRAP staining of decalcified specimens, respectively. A color image accompanies the online version of this article.
Techniques Used: Micro-CT, Expressing, Immunostaining, Staining

Figure Legend Snippet: A-H These (A-D) lower-magnification and (E-H) higher-magnification images of bone defect regions were taken of sections with osteocalcin immunostaining (A, B, E, F) at 4 weeks and (C, D, G, H) at 8 weeks after implantation of (A, C, E, G) OCP/Gel composites and (B, D, F, H) Gel. Osteocalcin-positive cells were observed more in the OCP/Gel group than in the Gel group at both 4 and 8 weeks. The open squares indicate the areas shown as magnified images in figures A-D. The black arrows indicate osteocalcin-positive cells. The arrowheads indicate the edge of the defects. (A-D) ×2 magnification, (E-H) ×10 magnification. Scale bars = (A-D) 1 mm and (E-H) 100 µm. A color image accompanies the online version of this article.
Techniques Used: Immunostaining

Figure Legend Snippet: This graph shows quantitative analysis of the number of osteocalcin-positive cells in the defect region after implantation of OCP/Gel composites and Gel at 4 and 8 weeks.
Techniques Used:
antibody against bovine osteocalcin (TaKaRa)


Structured Review

Antibody Against Bovine Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against bovine osteocalcin/product/TaKaRa
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Platelet-derived growth factor-BB regenerates functional periodontal ligament in the tooth replantation"
Article Title: Platelet-derived growth factor-BB regenerates functional periodontal ligament in the tooth replantation
Journal: Scientific Reports
doi: 10.1038/s41598-022-06865-6

Figure Legend Snippet: PDGF-BB decreases osteocalcin-positive cells and β-catenin accumulation in nucleus in vivo. ( A ) Representative images of sections immunostained for osteocalcin (OCN). Sections were immunostained with primary anti-OCN antibody and peroxidase-conjugated secondary antibody, and the immune complex was visualized with DAB substrate. The sections were then counterstained with haematoxilin. Pictures were taken of periodontal ligament (PDL) of the mesial root of the replanted teeth in the AC (a) and PDGF-BB (b) groups 3 days after tooth replantation. ( B ) Representative images of sections immunostained for β-catenin. Sections were incubated with primary anti-β-catenin antibody and secondary Alexa 488-conjugated antibody, and then counterstained with DAPI. DAPI (Ba and Bd), ß-catenin (Bb and Be), and overlay (Bc and Bf) images of the periodontal tissues. Pictures were taken of PDL of the mesial root of the replanted teeth day 3 in the AC (a-c) and PDGF-BB (d-f) groups. White arrows indicate nuclear b-catenin positive cells. B bone, Cm cementum, D dentine.
Techniques Used: In Vivo, Incubation
antibody against osteocalcin (TaKaRa)


Structured Review

Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Scara3 regulates bone marrow mesenchymal stem cell fate switch between osteoblasts and adipocytes by promoting Foxo1"
Article Title: Scara3 regulates bone marrow mesenchymal stem cell fate switch between osteoblasts and adipocytes by promoting Foxo1
Journal: Cell Proliferation
doi: 10.1111/cpr.13095

Figure Legend Snippet: Overexpression of Scara3 alleviated the bone loss and MAT accumulation in OVX mice. AAVs‐ Scara3 or AAVs‐control was injected into femoral bone marrow cavity of OVX mice. n = 5 per group. (A) Scara3 distribution in femoral. (B) Scara3 protein level in femoral BMSCs. (C) Quantification of Scara3 protein expression. (D) Representative micro‐CT images. (E‐H) Quantitative micro‐CT analysis of trabecular BV/TV (E), Tb. Th (F), Tb.N (G), Tb. Sp (H) bone microarchitecture in femora. n = 5 per group. (I‐J) Representative images and quantitative analysis of calcein double labelling. Scale bar = 100 µm. (K‐L) Representative images of HE staining and qualitative analysis of the number of adipocytes per square millimetre. Scale bar = 125 µm. (M‐N) Representative images of cells with positive OCN staining and the number of osteoblasts per millimetre of bone surface. Red arrowhead indicates osteocalcin‐positive–staining cells. Scale bar = 62.5 µm. n = 5 per group. All data were shown by mean ± SD. * P < .05, ** P < .01, *** P < .001, ANOVA
Techniques Used: Over Expression, Injection, Expressing, Micro-CT, Staining
![... per millimetre of bone surface. Red arrowhead indicates osteocalcin‐positive–staining cells. Scale bar = 62.5 µm. n = ... Overexpression of Scara3 mitigated the bone loss in aged mice. (A) Scara3 mRNA expression level in BMSCs of young and aged mice. (B‐C) The protein expression and quantitative analysis of Scara3 in BMSCs of young and aged mice. (D‐S) AAVs‐ Scara3 or AAVs‐control was injected into femoral bone marrow cavity of 15‐mo aged mice. n = 5 per group. (D) Scara3 distribution in femoral. (E‐F) Scara3 protein and quantification of BMSCs. (G) Representative micro‐CT images. (H‐K) Quantitative micro‐CT analysis of trabecular BV/TV (H), Tb. Th (I), Tb.N (J), Tb. Sp (K) bone microarchitecture in femora. n = 5 per group. (L‐M) Representative images and quantitative analysis of calcein double labelling. Scale bar = 100 µm. (N‐O) Representative images of HE staining and qualitative analysis of the number of adipocytes per square millimetre. Scale bar = 125 µm. (P‐Q) Representative images of cells with positive OCN staining and the number of osteoblasts per millimetre of bone surface. Red arrowhead indicates osteocalcin‐positive–staining cells. Scale bar = 62.5 µm. n = 5 per group. All data were shown by mean ± SD. * P < .05, ** P < .01, *** P < .001, Student's t test. [Correction added on 26 July 2021, after first online publication: Figure 8 was a duplicate of Figure 7. It has now been corrected.]](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9663/pmc08349663/pmc08349663__CPR-54-e13095-g005.jpg)
Figure Legend Snippet: Overexpression of Scara3 mitigated the bone loss in aged mice. (A) Scara3 mRNA expression level in BMSCs of young and aged mice. (B‐C) The protein expression and quantitative analysis of Scara3 in BMSCs of young and aged mice. (D‐S) AAVs‐ Scara3 or AAVs‐control was injected into femoral bone marrow cavity of 15‐mo aged mice. n = 5 per group. (D) Scara3 distribution in femoral. (E‐F) Scara3 protein and quantification of BMSCs. (G) Representative micro‐CT images. (H‐K) Quantitative micro‐CT analysis of trabecular BV/TV (H), Tb. Th (I), Tb.N (J), Tb. Sp (K) bone microarchitecture in femora. n = 5 per group. (L‐M) Representative images and quantitative analysis of calcein double labelling. Scale bar = 100 µm. (N‐O) Representative images of HE staining and qualitative analysis of the number of adipocytes per square millimetre. Scale bar = 125 µm. (P‐Q) Representative images of cells with positive OCN staining and the number of osteoblasts per millimetre of bone surface. Red arrowhead indicates osteocalcin‐positive–staining cells. Scale bar = 62.5 µm. n = 5 per group. All data were shown by mean ± SD. * P < .05, ** P < .01, *** P < .001, Student's t test. [Correction added on 26 July 2021, after first online publication: Figure 8 was a duplicate of Figure 7. It has now been corrected.]
Techniques Used: Over Expression, Expressing, Injection, Micro-CT, Staining
rimary antibody against osteocalcin (TaKaRa)


Structured Review
Rimary Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rimary antibody against osteocalcin/product/TaKaRa
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
antibody against osteocalcin (TaKaRa)


Structured Review

Antibody Against Osteocalcin, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against osteocalcin/product/TaKaRa
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Celastrol regulates bone marrow mesenchymal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing PGC-1α signaling"
Article Title: Celastrol regulates bone marrow mesenchymal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing PGC-1α signaling
Journal: Aging (Albany NY)
doi: 10.18632/aging.103590

Figure Legend Snippet: Celastrol promoted the osteogenic differentiation of BM-MSCs in vitro . ( A ) BM-MSCs were seeded into 96-well plates at a density of 8×10 3 cells/well and treated with different concentrations of Celastrol for 48 h. Cell viability was determined using CCK-8 assay. ( B , C ) Representative images of Alizarin Red S staining ( B ) and quantitative analysis ( C ) of matrix mineralization of BM-MSCs cultured in the osteogenesis induction medium for 21 days. Scale bar: 100 μm. ( D , E ) Analysis of ALP activity ( D ) and osteocalcin secretion ( E ) of BM-MSCs cultured in the osteogenesis induction medium for 48 hours (n = 3 per group). ( F ) qRT-PCR analysis of the relative levels of Osterix and Runx2 mRNA expression in BM-MSCs cultured in the osteogenesis induction medium for 48 hours (n = 3 per group). Results are shown as mean ± SD. Statistical significance was determined using analysis of variance (one-way ANOVA). * P < 0.0001 compared with control.
Techniques Used: In Vitro, CCK-8 Assay, Staining, Cell Culture, Activity Assay, Quantitative RT-PCR, Expressing

Figure Legend Snippet: Celastrol regulated the differentiation of BM-MSCs by activating PGC-1 α signaling. ( A ) Expression levels of PGC-1 α , UCP2 and Catalase in BM-MSCs treated with the vehicle or Celastrol (1.0 μM, 48 hours) (n = 3 per group). ( B ) Western blotting analysis of the protein levels of PGC-1 α of BM-MSCs treated with the vehicle or Celastrol (1.0 μM, 48 hours). ( C ) Western blotting analysis for the detection of PGC1α acetylation levels in PGC1α immunoprecipitates obtained from BM-MSCs transfected with pcDNA-Flag-PGC1α and treated with the vehicle or Celastrol (1.0 μM, 48 hours). ( D ) Western blotting analysis for the detection of pAMPK in BM-MSCs treated with the vehicle or Celastrol (1.0 μM, 48 hours). The levels of pAMPK were quantified using ImageJ software and were normalized to total AMPK levels ( D , bottom). ( E ) Western blotting analysis of the protein levels of SIRT-1 in BM-MSCs treated with the vehicle or Celastrol (1.0 μM, 48 hours). ( F ) Western blotting analysis of the relative levels of PGC-1 α in BM-MSCs transfected with PGC-1 α siRNA. ( G , H ) Representative images of Alizarin Red staining ( G ) and quantitative analysis ( H ) of matrix mineralization of BM-MSCs cultured in the osteogenesis induction medium for 21 days. Scale bar: 100 μm. ( I , J ) Representative images of Oil Red O staining of lipids ( I ) and quantification of the number of spots ( J ) on BM-MSCs cultured in the adipogenesis induction medium for 14 days. Scale bar: 100 μm. ( K ) PGC-1α-knockout (PGC-1α -/- ) mice (2 month old) and WT mice (2 month old) were ovariectomized. 12 weeks later, they were intraperitoneally injected with Celastrol (200 μg/kg) or DMSO (control) every two days for 4 weeks. H&E staining (top) and osteocalcin immunohistochemical staining (bottom) of the bone were conducted to evaluate the numbers and area covered by adipocytes and osteoblasts after Celastrol treatment. Scale bar: 100 μm. Data are presented as mean ± SD. Statistical significance was determined using the t -test. *P < 0.0001; # P < 0.001 compared with control.
Techniques Used: Expressing, Western Blot, Transfection, Software, Staining, Cell Culture, Knock-Out, Injection, Immunohistochemical staining

Figure Legend Snippet: Administration of Celastrol alleviated bone loss and MAT accumulation in aged mice. ( A ) mRNA expression level of PGC-1 α in the BM-MSCs determined using qRT-PCR (n = 3 per group). ( B – G ) Representative μCT images ( B ) and quantitative μCT analysis of trabecular ( C – E ) and cortical ( F , G ) bone microarchitecture in the femora of Celastrol-treated mice. n = 6-7 per group. ( H – I ) Three-point bending measurement of femur maximum load ( H ) and stiffness ( I ). n = 5 per group. ( J , K ) Representative μCT images ( J ) and quantification of the ratio of bone volume to tissue volume ( K ) of L4 vertebrae (Vt. BV/TV). n = 6 per group. ( L ) Representative images of H&E staining ( L , top) and osteocalcin immunohistochemical staining ( L , bottom). Scale bars: 100 μm. n = 5 per group. Data are presented as mean ± SD. Statistical significance was determined using analysis of variance (one-way ANOVA). # P < 0.001; **P < 0.01; *P < 0.05.
Techniques Used: Expressing, Quantitative RT-PCR, Staining, Immunohistochemical staining

Figure Legend Snippet: Celastrol treatment increased bone formation and reduced bone marrow fat in OVX mice. ( A ) mRNA expression level of PGC-1 α in the BM-MSCs determined using qRT-PCR (n = 3 per group). ( B – G ) Representative μCT images ( B ) and quantitative μCT analysis of trabecular ( C – E ) and cortical ( F , G ) bone microarchitecture of the femora of Celastrol-treated mice. n = 6-7 per group. ( H – I ) Three-point bending measurement of femur maximum load ( H ) and stiffness ( I ). n = 5 per group. ( J , K ) Representative μCT images ( J ) and quantification of the ratio of bone volume to tissue volume ( K ) of L4 vertebrae (Vt. BV/TV). n = 6 per group. ( L ) Representative images of H&E staining ( L , top) and osteocalcin immunohistochemical staining ( L , bottom). Scale bars: 100 μm. n = 5 per group. Data are presented as mean ± SD. Statistical significance was determined using analysis of variance (one-way ANOVA). # P < 0.001; **P < 0.01, *P < 0.05.
Techniques Used: Expressing, Quantitative RT-PCR, Staining, Immunohistochemical staining